Syntekabio will present its innovative AI drug discovery platforms, DeepMatcher® and NEO-ARS™, at the UKC 2022. The event is designed to foster collaboration between U.S. and Korean professionals, featuring opportunities for networking and showcasing cutting-edge technologies in drug discovery. Kilyoung Kim, PhD, will represent the company at the symposium.
Syntekabio, a leading global company in AI drug discovery and development, will showcase its advanced AI drug discovery cloud platforms, DeepMatcher® and NEO-ARS™, at the upcoming U.S.-Korea Conference (UKC) on August 19, 2022, in Arlington, Virginia. The symposium will facilitate collaboration among American and Korean professionals in science, technology, and entrepreneurship, providing networking opportunities for businesses and investors.
The U.S.-Korea Conference (UKC) serves as a platform for professionals from various fields to explore recent developments and foster partnerships. This event not only promotes U.S.-Korea cooperation but also highlights innovative technologies and entrepreneurial opportunities within the drug discovery sector. Syntekabio aims to present groundbreaking advancements in its AI-based drug discovery methods, enhancing cross-border business prospects.
Syntekabio’s participation in the UKC 2022 signifies its commitment to advancing drug discovery through AI technology. The company’s platforms, DeepMatcher® and NEO-ARS™, promise to revolutionize pharmaceutical development, demonstrating the potential for AI in healthcare. Interested parties are encouraged to reach out for more information on Syntekabio’s initiatives and to schedule meetings with its leadership during the conference.
Original Source: www.globenewswire.com
